Exicure (XCUR) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Exicure (XCUR) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
762,369.55 Bn |
762,369.51 Bn |
- |
- |
| 2 |
Belite Bio |
55,096.00 Bn |
55,096.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,755.80 Bn |
17,755.79 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,486.00 Bn |
3,485.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,737.42 Bn |
1,737.41 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,551.28 Bn |
1,551.26 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
227.32 Bn |
227.31 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
110.84 Bn |
103.59 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
91.71 Bn |
91.71 Bn |
- |
- |
| 10 |
Exicure |
17.53 Mn |
14.92 Mn |
- |
-160.73% |
| Date | Value |
|---|
| Mar 31, 2026 |
-160.73% |
| Dec 31, 2025 |
59.64% |
| Sep 30, 2025 |
-123.37% |
| Jun 30, 2025 |
-336.83% |
| Mar 31, 2025 |
463.09% |
| Dec 31, 2024 |
-382.92% |
| Sep 30, 2024 |
79.24% |
| Jun 30, 2024 |
89.59% |
| Mar 31, 2024 |
81.19% |
| Dec 31, 2023 |
-108.08% |
| Sep 30, 2023 |
-1.86% |
| Jun 30, 2023 |
22.84% |
| Mar 31, 2023 |
47.21% |
| Dec 31, 2022 |
233.06% |
| Sep 30, 2022 |
78.07% |
| Jun 30, 2022 |
47.65% |
| Mar 31, 2022 |
33.09% |
| Dec 31, 2021 |
-8.99% |
| Sep 30, 2021 |
-166.73% |
| Jun 30, 2021 |
-230.99% |
